The 3 most recent market catalysts affecting $STLN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 80
Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year Guidance
Starling Oncology announced its Q3 2026 financial results, highlighting a significant 44% year-over-year increase in specialty pharmacy revenue to $109 million, alongside a 24% gro…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 60
Needham Maintains Buy on Starling Oncology, Raises Price Target to $9
Needham analyst Matthew Shea maintained a 'Buy' rating on Starling Oncology (STLN) and raised the price target from $7 to $9. This upgrade signals increased confidence from a reput…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 92
Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY
Starling Oncology (STLN) announced its Q2 financial results, reporting a narrower loss per share of $(0.08) compared to $(0.15) in the prior year, representing a 46.67% improvement…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.